Immunoadsorption in systemic lupus erythematosus: Different techniques and their current role in medical therapy

Therapeutic Apheresis

Volumn 7, Issue 2, 2003, Pages 183-188

  Gaubitz, Markus ^a   Schneider, K Matthias ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Autoantibodies; Immune complex; Immunoadsorption; Plasmapehresis; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C1Q; CYCLOPHOSPHAMIDE; DEXTRAN SULFATE; IMMUNOGLOBULIN G; PHENYLALANINE; POLYVINYL ALCOHOL; PROTEIN A; TRYPTOPHAN;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BIOCOMPATIBILITY; EXTRACORPOREAL CIRCULATION; HUMAN; IMMUNOADSORPTION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; PLASMAPHERESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

HUMANS; IMMUNOSORBENT TECHNIQUES; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLASMAPHERESIS;

EID: 0037631827     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00040.x     Document Type: Article

References (37)

1. Jones JV, Cumming RH, Bacon PA et al. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med 1979;192:555-76.
2. Lockwood CM, Worledge S, Nicholas A, Cotton C, Peters DK. Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 1979;300:524-30.
3. Norrgren K, Strand SE, Ingvar C. Contrast enhancement in RII and modification of the therapeutic ratio in RIT. A theoretical evaluation of simulated extracorporeal immunoadsorption. Antibody, Immunoconjugates Radiopharmaceuticals 1992;5:61-73.
4. Leaker BR, Becker GJ, Dowling JP, Kincaid-Smith PS. Rapid improvement in severe lupus glomerular lesions following intensive plasma exchange associated with immunosuppression. Clin Nephrol 1986;25:236-44.
5. Sanaka T, Wakai S, Teraoka S, Takuma T, Sugino N, Agishi T. Effect of therapeutic plasma exchange on immunological and renal pathological findings in patients with lupus nephritis. In: Rock G, ed. Apheresis New York: Alan R Liss Inc., 1990;351-3.
6. Charlton B, Schindhelm K, Smeby LC, Farrell PC. Analysis of immunoglobulin G kinetics in the non-steady state. J Lab Clin Med 1985;105:312-20.
7. Terman DS, Garcia-Rinaldi R, Dannemann B et al. Specific suppression of antibody rebound after extracorporeal immunoadsorption. I. Comparison of single versus comination chemotherapeutic agents. Clin Exp Immunol 1978;34:32-41.
8. Koo AP. Therapeutic apheresis in autoimmune and rheumatic diseases. J Clin Apheresis 2000;15:18-27.
9. Sawada K, Malchesky PS, Nosé Y. Available removal systems. State of the art. In: Nydegger UE, ed. Therapeutic Hemapheresis in the 1990s, Curr Stud Hematol Blood Transf no. 57 Basel: Karger, 1990;51-113.
10. Singer DRJ, Roberts D, Cohen J. Infective complications of plasma exchange: a prospective study. Arthritis Rheum 1987;30:443-7.
11. Gaubitz M, Schmitz-Linneweber B, Perniok A, Fischer R, Schneider M. IG-Immunoadsorption in SLE. First experiences (Abstract). Lupus 1995;4:S113.
12. Gjörstrup P & Watt RM. Therapeutic protein A immunoadsorption. A Rev Transfus Sci 1990;11:281-302.
13. Hiepe F, Schössler W, Apostoloff E, Precht K. Development of a C1q-adsorbent for the selective removal of circulating immune complexes. Biomat Art Cells Art Org 1990;18:52934.
14. Usada M, Maeda K, Sezaki R et al. Clinical application of newly developed absorbent resin (I-02) for regeneration of plasma from auto-immune disease patients. In: Oda T, ed. Therapeutic Plasmapheresis Stuttgart: Schattauer Verlag, 1982;105-10.
15. Lazarus HM, Cohen SB, Clegg DO et al. Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patients. Transfusion 1990;31:122-8.
16. Suzuki K, Hara M, Harigai M et al. Continuous removal of anti-DNA antibody, using a new extracorporeal immunoadsorption system, in patients with systemic lupus erythematosus. Arthritis Rheum 1991;34:1546-52.
17. Avenhaus B, Avenhaus W, Schneider M, Domschke W, Gaubitz M. Development of an in vitro miniature model to simulate immunoadsorption in patients with systemic lupus erythematosus. J Clin Apher 2002;17:183-9.
18. Ikonomov V, Samtleben W, Schmidt B, Blumenstein M, Gurland HJ. Adsorption profile of commercially available adsorbents: an in vitro evaluation. Intern J Artif Org 1992;15:312-19.
19. Kinoshita M, Aotsuka S, Funahashi T, Tani N, Yokohari R. Selective removal of anti-double-stranded DNA antibodies by immunoadsorption with dextran sulphate in a patient with systemic lupus erythematosus. Ann Rheum Dis 1989;48:856-60.
20. Terman DS, Stewart I, Robinette J, Carr R, Harbeck R. Specific removal of DNA antibodies in vivo with an extracorporeal immuno-adsorbent. Clin Exp Immunol 1976;24:231-7.
21. Traeger J, Laville M, Serres PF et al. A new device for specific extracorporeal immunoadsorption of anti-DNA antibodies. Ann Med Intern 1992;143:9-12.
22. McLeod B, Lewis E, Schnitzer T et al. Therapeutic immunoadsorption of anti-native DNA antibodies in SLE. Clinical studies with a device utilizing monoclonal anti-idiotypic antibody. Arthritis Rheum 1988;31:S15.
23. Hashimoto H, Tsuda H, Kanai Y et al. Selective removal of anti-DNA and anticardiolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythematosus. J Rheumatol 1990;18:545-51.
24. Tokuda M, Inoh M, Akashi Y, Seto K, Kurata N, Takahara J. Randomized open trial to elucidate the effect of immunoadsorption anti-DNA antibodies in SLE patients. Jpn J Apher 1997;16:183-4.
25. Waldendorf M, Schneider M, Lohmann J. Immunadsorbent perfusion therapy of patients with SLE. Clin Exp Rheumatol 1987;5:208.
26. Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S. Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57:578-81.
27. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
28. Schneider KM. Plasmapheresis and immunoadsorption. Different techniques and their current role in medical therapy. Kidney Int 1998;53:61-5.
29. Langone JJ. Protein A of Staphyloccocus aureus and related immunoglobulin receptors produced by streptococci and pneumoccoci. Adv Immunol 1982;32:157-252.
30. Nilsson IM, Sundqvist SB, Ljung R, Holmberg L, Freiburghaus C, Björlin G. Suppression of secondary antibody response by intravenous immunoglobulin in a patient with haemophilia B and antibodies. Scand J Haematol 1983;30:458-64.
31. Palmer A, Cairns T, Dische F et al. Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 1991;6:536-42.
32. Palmer A, Gjorstrup P, Severn A, Welsh K, Taube D. Treatment of systemic lupus erythematosus by extracorporeal immunoadsorption. Lancet 1988;ii:272.
33. Braun N, Erley C, Klein R, Kötter I, Saal J, Risler T. Immunoadsorption onto Protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant 2000;15:1367-72.
34. Gaubitz M, Schmitz-Linneweber B, Perniok A, Fischer R, Schneider M. Ig-Immunoadsorption in SLE: First Experiences. Lupus 1995;4(Suppl):S113.
35. Gaubitz M. Therapieeffekte verschiedener Adsorber beim systemischen Lupus erythematodes. In: Brunkhorst R, Koch KM, Koll R, eds. Klinische Immunoadsorption Stuttgart: Wissenschaftliche Verlagsgesellschaft, 2000;90-3.
36. Gaubitz M, Seidel M, Kummer S et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 1998;11:495-501.
37. Pfueller B, Wolbart K, Bruns A, Burmester GR, Hiepe F. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum 2001;44:1962-3.